Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 24
- Registration Number
- NCT00000944
- Locations
- 🇺🇸
Montefiore Med. Ctr. - AECOM, Bronx, New York, United States
🇺🇸Jacobi Med. Ctr., Bronx, New York, United States
🇺🇸HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States
A Clinical Trial of Alternating and Intermittent Regimens of 2',3'-Dideoxycytidine and 3'-Azido-3'-Deoxythymidine in the Treatment of Patients With AIDS and Advanced ARC
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 112
- Registration Number
- NCT00000718
- Locations
- 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 6
- Registration Number
- NCT00000680
- Locations
- 🇺🇸
Univ of Pittsburgh Med School, Pittsburgh, Pennsylvania, United States
The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 105
- Registration Number
- NCT00001067
- Locations
- 🇺🇸
Alabama Therapeutics CRS, Birmingham, Alabama, United States
🇺🇸Ucsd, Avrc Crs, San Diego, California, United States
🇺🇸Stanford CRS, Palo Alto, California, United States
A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 2100
- Registration Number
- NCT00000625
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸UCSD Maternal, Child, and Adolescent HIV CRS, San Diego, California, United States
🇺🇸Ucsd, Avrc Crs, San Diego, California, United States
The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 32
- Registration Number
- NCT00001024
- Locations
- 🇺🇸
Univ of Illinois, Chicago, Illinois, United States
🇺🇸Univ of Maryland at Baltimore, Baltimore, Maryland, United States
🇺🇸Duke Univ Med Ctr, Durham, North Carolina, United States
A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 26
- Registration Number
- NCT00000973
- Locations
- 🇺🇸
Unc Aids Crs, Chapel Hill, North Carolina, United States
🇺🇸Memorial Sloan-Kettering Cancer Ctr., New York, New York, United States
A Comparison of Zidovudine (AZT) Used Alone or in Combination With Didanosine (ddI) or Dideoxycytidine (ddC) in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 1200
- Registration Number
- NCT00001022
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸AIDS Research Alliance - Chicago, Chicago, Illinois, United States
🇺🇸Community Consortium of San Francisco, San Francisco, California, United States
The Safety and Effectiveness of Zidovudine in the Treatment of Patients With Early AIDS Related Complex
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 538
- Registration Number
- NCT00001011
- Locations
- 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Harbor UCLA Med Ctr, Torrance, California, United States
A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 400
- Registration Number
- NCT00000770
- Locations
- 🇺🇸
Saint Clare's Hosp and Health Ctr, New York, New York, United States
🇺🇸Cornell Univ Med Ctr, New York, New York, United States
🇺🇸Summitt Med Ctr / San Francisco Gen Hosp, Oakland, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.